← All companies

LABT

Lakewood-Amedex Biotherapeutics, Inc.

LABT Nasdaq Pharmaceutical Preparations EDGAR ↗

$2.16

+0.14 +6.93%

Key statistics

from XBRL data in SEC filings

Market cap

$15.1M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$11.7K

Total assets

$196K

Gross margin

—

52-week range

$1.66 – $98.20

Recent SEC filings

34 most recent

Annual, quarterly & current reports

8-K Regulation FD disclosure Jul 15, 2026 8-K Modified rights of security holders; Amended charter or bylaws Jun 17, 2026 10-Q Quarter ended 2026-03-31 May 22, 2026 8-K Director or officer change Apr 28, 2026

Other filings

PRE 14A PRELIMINARY PROXY STATEMENT Jul 30, 2026 SCHEDULE 13G Jun 23, 2026 424B3 PROSPECTUS SUPPLEMENT Jun 22, 2026 424B3 PROSPECTUS SUPPLEMENT Jun 22, 2026 424B3 PROSPECTUS SUPPLEMENT May 26, 2026 424B3 PROSPECTUS SUPPLEMENT May 26, 2026 424B4 PROSPECTUS May 14, 2026 EFFECT May 13, 2026 CORRESP May 12, 2026 UPLOAD May 8, 2026 4 May 6, 2026 3 May 6, 2026 3 May 1, 2026 3 May 1, 2026 3 May 1, 2026 3 May 1, 2026 S-1 REGISTRATION STATEMENT May 1, 2026 424B3 PROSPECTUS SUPPLEMENT Apr 30, 2026 424B4 PROSPECTUS Apr 23, 2026 CERT Apr 22, 2026 EFFECT Apr 17, 2026 8-A12B FOR REGISTRATION OF CERTAIN CLASSES Apr 17, 2026 S-1/A REGISTRATION STATEMENT Apr 6, 2026 S-1/A REGISTRATION STATEMENT Apr 1, 2026 S-1/A REGISTRATION STATEMENT Mar 11, 2026 S-1/A REGISTRATION STATEMENT Feb 13, 2026 S-1/A REGISTRATION STATEMENT Feb 5, 2026 S-1 REGISTRATION STATEMENT Jan 9, 2026 DRS/A Oct 17, 2025 DRS Jul 31, 2025